Drug Profile
Elotuzumab - AbbVie/Bristol-Myers Squibb
Alternative Names: BMS-901608; Empliciti; HuLuc-63; PDL-063Latest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD319 antigen modulators; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 12 Dec 2023 Washington University School of Medicine, Bristol-Myers Squibb and Celgene suspends a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada and USA, due to poor accual (NCT03030261)
- 06 Oct 2023 Amgen in collaboration with Bristol-Myers Squibb and Hospital District of Helsinki and Uusimaa completes a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Finland and Sweden (IV) (NCT03155100)
- 29 Mar 2023 Bristol-Myers Squibb terminates a phase II trial as sponsor no longer providing drug for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03411031)